Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 268

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 268
---
 management
believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made.
These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates.

| c. | Financial statements in United States dollars: |

The functional and reporting currency
of the Company is the United States dollar (the “USD” or “U.S dollar”) as the U.S. dollar is the currency of the
primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.

The Company transactions and balances
denominated in U.S. dollars are presented at their original amounts. Non-U.S. dollar transactions and balances have been remeasured to
U.S. dollars in accordance with ASC 830, Foreign Currency Matters (“ASC 830”) of the Financial Accounting Standards
Board (the “FASB”). All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-U.S.
dollar currencies are reflected in the statements of comprehensive loss as financial income or expenses, as appropriate.

| d. | Cash and cash equivalents: |

Cash equivalents are short-term highly
liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.

| e. | Fair Value Measurements: |

The carrying values of Company’s
financial assets and liabilities, including cash and cash equivalents, other current assets, trade payables, other accounts payable and
short-term loan, approximate their fair value due to the short-term maturity of these instruments. Fair value is defined as the price
that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants
at the reporting date. Assets and liabilities recorded at fair value in the financial statements are categorized based upon the level
of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity
with the inputs to the valuation of these assets or liabilities as follows:

| Level 1 | – | Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; |

| Level 2 | – | Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable inputs for similar assets or liabilities. These include